Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck. 2005

Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
Department of Head and Neck Surgery, Department of Head and Neck Surgery, Gustave-Roussy Institute, 39 rue Camille-Desmoulins, 94805 Villejuif Cedex, France.

BACKGROUND Induction chemotherapy may contribute to decreased local and distant recurrences in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) resectable for cure. METHODS Patients with previously untreated locally advanced stage III-IV (N0-2, M0) SCCHN received a dose-dense sequential regimen combining cisplatin/5-fluorouracil followed by bleomycin/methotrexate/hydroxyurea. Induction chemotherapy was followed by locoregional surgery and/or radiation therapy. RESULTS Among 37 patients, 23 (62%) had T4 primary tumors. Grade 3 to 4 asymptomatic hematologic toxicity occurred in less than 15% of patients. Nonhematologic toxicities were limited to grade 1 to 2 in less than 20% of patients. In the overall cohort (intent-to-treat; n = 35), 24 (68.5%) of 35 patients had objective clinical responses, including nine complete responses (25.7%). Fifty-seven percent of patients were free of disease at 2.5 years. CONCLUSIONS Sequential induction chemotherapy is feasible and active in patients with locally advanced head and neck cancers and may further include recent compounds such as taxanes.

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility

Related Publications

Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
March 2016, Cancer treatment reviews,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
January 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
February 2021, Japanese journal of clinical oncology,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
July 2012, Seminars in radiation oncology,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
March 1986, International journal of radiation oncology, biology, physics,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
December 1979, The Laryngoscope,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
October 2014, Anticancer research,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
May 2021, BMC cancer,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
November 2011, Head & neck oncology,
Sandrine Faivre, and Adina Marti, and Olivier Rixe, and François Janot, and Morbize Julieron, and Michel Gatineau, and Stéphane Temam, and Jean-Pierre Armand, and Christian Domenge, and Bernard Luboinski, and Eric Raymond
April 2015, The Lancet. Oncology,
Copied contents to your clipboard!